Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication
Clinical and Molecular Hepatology · 01.07.2024 · 30 (3) · 326-344
DOI: 10.3350/cmh.2024.0155 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Molecular Hepatology, erschienen am 01.07.2024. Verfasst von Chung-Feng Huang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Antiviral Agents, Hepacivirus. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 139 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: National Sun Yat-sen University, Ministry of Education, Israel Science Foundation.
Abstract (Originalsprache)
Hepatitis C virus (HCV) infection is one of the major etiologies of hepatocellular carcinoma (HCC) with approximately 30% of HCC being due to HCV infection worldwide. HCV eradication by antivirals greatly reduces the risk of HCC; nevertheless, HCC remains to occur in chronic hepatitis C (CHC) patients who have achieved a sustained virological response (SVR). The proportion of post-SVR HCC among newly diagnosed HCC patients is increasing in the direct-acting antiviral (DAA) era and might be due to preexisting inflammatory and fibrotic liver backgrounds, immune dysregulation between host and virus interactions, as well as host epigenetic scars, genetic predispositions and alternations. By means of applying surrogate markers and adopting risk stratification, HCC surveillance should be consistently performed in high-risk populations. In this review, we discuss the possible molecular mechanism, risk factors, and HCC surveillance strategy for HCC development after HCV eradication in CHC patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hepatobiliary Division, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung, Taiwan.
- College of Medicine and Center for Liquid Biopsy and Cohort Research, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Faculty of Internal Medicine and Hepatitis Research Center, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.
- Ph.D. Program in Translational Medicine, College of Medicine, Kaohsiung Medical University and Academia Sinica, Kaohsiung, Taiwan.
- Molecular Virology Lab, The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- School of Medicine and Doctoral Program of Clinical and Experimental Medicine, College of Medicine and Center of Excellence for Metabolic Associated Fatty Liver Disease, National Sun Yat-sen University, Kaohsiung, Taiwa…
Förderung
- National Sun Yat-sen University
- Ministry of Education
- Israel Science Foundation
- AbbVie
- BMS
- Gilead
- Merck and Roche diagnostics
Zitieren
APA
Huang, C. F., Awad, M. H., Gal-Tanamy, M., & Yu, M. L. (2024). Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clinical and Molecular Hepatology, 30(3), 326-344. https://doi.org/10.3350/cmh.2024.0155
Vancouver
Huang CF, Awad MH, Gal-Tanamy M, Yu ML. Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication. Clinical and Molecular Hepatology. 2024;30(3):326-344. doi:10.3350/cmh.2024.0155
BibTeX
@article{Huang2024,
author = {Huang, Chung-Feng and Awad, Manar Hijaze and Gal-Tanamy, Meital and Yu, Ming-Lung},
title = {Unmet needs in the post-direct-acting antivirals era: The risk and molecular mechanisms of hepatocellular carcinoma after hepatitis C virus eradication},
journal = {Clinical and Molecular Hepatology},
year = {2024},
volume = {30},
number = {3},
pages = {326--344},
doi = {10.3350/cmh.2024.0155}
}
EUVIMED